Septic ShockNCT02835157
Balanced Crystalloid vs. Saline in Children With Septic Shock
A study testing Balanced crystalloid solution and 0.9%sodium chloride in people with Septic Shock and Shock, run by All India Institute of Medical Sciences at 4 sites in India.
Trial summary
Fluid resuscitation is the cornerstone of pediatric shock management; current practices of fluid resuscitation in children are not evidence based. Normal saline is the preferred crystalloid recommended during initial resuscitation in shock, as the incidence of hyponatremia is lower with normal saline compared to all… Read more about this study
- Who is it for?
- Ages 2 months to 15 years
- Conditions the study is for
- Septic Shock, Shock
- What is being tested?
- Balanced crystalloid solution and 0.9%sodium chloride
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 708 participants
- Where
- 4 sitesIndia
- Study dates
- 1 Apr 2017to 15 Jan 2020
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 2 months to 15 years
- All sexes
- No healthy volunteers
- Child
Who may be able to join
- Children 2 month to ≤ 15 years with features of septic shock - defined as children who have a suspected infection manifested by hypothermia or hyperthermia and have at least two clinical signs of decreased perfusion with or without hypotension
Who cannot join
- Children receiving fluid boluses before enrollment
- Children with cardiogenic shock
- Known patient with chronic kidney disease with baseline deranged renal function (eGFR < 90 ml/1.73 m2/min)
- Severe malnutrition
- Children whose parents refuse to give an informed consent
Trial locations and contacts
4 sites in 1 country.
India4 sites
St Johns Medical College and Hospital
Bengaluru, Karnataka, 560034
PGIMER
Chandigarh
All India Institute of Medical Sciences
New Delhi, National Capital Territory of Delhi, 110029
JIPMER
Puducherry, 605006
About this study
Official title: Multiple Electrolyte Solution vs. Saline in Pediatric Septic Shock
Fluid resuscitation is the cornerstone of pediatric shock management; current practices of fluid resuscitation in children are not evidence based. Normal saline is the preferred crystalloid recommended during initial resuscitation in shock, as the incidence of hyponatremia is lower with normal saline compared to all other fluids available and commonly used. However, normal saline has its own set of undesired physicochemical actions. Emerging data strongly indicate the increased incidence of hyperchloremia, metabolic acidosis and consequently, acute kidney injury associated with infusion of large volumes of normal saline. Balanced salt solutions or crystalloids, which have composition resembling plasma but lower chloride concentrations than normal saline, clearly decrease the risk of hyperchloremia and metabolic acidosis in adult as well as pediatric studies when used during the peri-operative period. The results favored balanced solutions in comparison to normal saline. Recent systematic reviews comparing balanced or buffered versus non-buffered fluids for surgery in adults favored the former solution as the metabolic derangements were less with the use of this type of fluid. In adult patients, the two solutions have been compared in various other settings as well such as in traumatic brain injury and in shock. The results favored balanced solutions in comparison to normal saline. However, in the non-surgical setting there is a paucity of evidence on the use of these solutions in children with shock and more evidence needs to be generated to support or refute the use of this fluid as compared to normal saline.
Given this background, the investigators decided to compare the effect of two solutions on the incidence of acute kidney injury in children resuscitated with either of the two fluids. Children receiving at least one fluid bolus at 20 ml/kg in the first hour would be enrolled and followed up for the proposed outcome variables. The investigators plan to enroll 708 patients over a period of 3 years. The investigators believe that the proposed study will provide answer to the research question of which of the fluids could be preferred for resuscitation.
Read the detailed description
Background
Fluid resuscitation is the cornerstone of pediatric shock management; current practices of fluid resuscitation in children are not evidence based. Emerging data strongly indicate the increased incidence of hyperchloremic metabolic acidosis and consequently, acute kidney injury associated with infusion of large volumes of normal saline in critically ill adults in shock. Balanced salt solutions or crystalloids, which have composition resembling plasma but lower chloride concentrations than normal saline, have shown to decrease the risk of hyperchloremia and metabolic acidosis in adult as well as pediatric studies when used during the peri-operative period. In adult patients, the two solutions have been compared in various other settings as well such as in traumatic brain injury and in shock. The results favored balanced solutions in comparison to normal saline. However, in the non-surgical setting there is a paucity of evidence on the use of these solutions in children with shock and more evidence needs to be generated to support or refute the use of this fluid as compared to normal saline.
Objectives
Primary To examine if use of 'balanced crystalloids (multiple electrolyte solution)" results in lower incidence of new or progressive Acute kidney injury (defined as increase in serum creatinine by > 0.3mg/dL within 48 hours or to 1.5 times baseline or more within the last 7 days or urine output less than 0.5 mL/kg/h for 6 hours) in the first seven days after initial fluid resuscitation as compared to saline.
Secondary
To evaluate the difference if any, between two fluid types with regard to the following secondary objectives such as:
- Incidence of hyperchloremia (defined as serum chloride levels >108 mEq/L) at 6, 24, 48 and 72 hrs of fluid resuscitation.
- Incidence of metabolic acidosis at 6, 24, 48 and 72 hrs of fluid resuscitation.
- Requirement of fluid boluses in first 6 hrs and total fluids in first 24 hours, 48 hours and 72 hours.
- Proportion of patients achieving the pre-determined therapeutic end points at 6, 24, 48 hours and 72 hours after fluid resuscitation.
- Need for inotrope therapy in first 7 days.
- Change in SOFA scores and PELOD scores at 24 hours and 48 hours.
- Time to resolution of AKI.
- In- ICU mortality rates.
- Ventilator free days, ICU free days and Hospital free days.
Site of study
Pediatric emergency and PICU, Department of Pediatrics, All India Institute of medical Sciences,New Delhi
Other sites
PGIMER, Chandigarh, JIPMER Puducherry and St Johns Medical College Bengaluru
Study Design
Randomized controlled trial (safety and superiority for kidney injury). Multicenter trial.
Study Duration
3 years
Study definitions
Septic shock is defined as children who have a suspected infection manifested by hypothermia or hyperthermia and have at least two clinical signs of decreased perfusion with or without hypotension such as decreased mental status, prolonged capillary refill of >2 secs (cold shock) or flash capillary refill (warm shock), diminished (cold shock) or bounding (warm shock) peripheral pulses, mottled cool extremities (cold shock), or decreased urine output of <1 ml/kg/hr).
Therapeutic end points
- Normal heart rate
- Appropriate-for-age mean arterial pressure (MAP) measured non-invasively;
- Normal pulses with no difference between peripheral and central pulses, warm extremities;
- Capillary refill time <2 seconds;
- Normal mental status;
- Urine output ≥ 1mL/kg/hr,
Hyperchloremia: Defined as serum chloride value of >108 meq/L, based on our laboratory cut off of 98-108 meq/L Metabolic acidosis: pH of less than 7.35 with serum bicarbonate < 24 meq/L with low to normal pCO2 (<40 mm Hg)
Acute kidney injury: An abrupt (within 48-hr) reduction in kidney function defined as an absolute increase in serum creatinine of more than or equal to 0.3 mg/dl, an increase in serum creatinine of more than or equal to 1.5 fold from the value preceding the abnormal value, or reduction in urine output (oliguria of less than 0.5 ml/kg per hour for >6-hr).
Enrollment
All children with features of shock as per standard definitions will be screened for eligibility. Of these, children who require at least one fluid bolus of 20 ml/kg will be enrolled. The eligible participants would be enrolled after obtaining informed consent from one of the parents.
Randomization
Once enrolled, the participants would be randomized into 2 groups. 'MES' or 'study group' will receive the balanced fluids and 'saline' or 'control group' will receive 0.9% saline. Process of randomization will be done by an investigator who will have no further role in collecting the baseline variables, applying intervention or analysis of outcome(s). Block randomization will be done in varying block sizes of 2 to 8. The random number table generated from computer software would be used for this purpose.
Sample size estimation
The investigators calculated that a sample size of 354 patients in each group (708 total) would be required to detect an absolute reduction in incidence of AKI from 25% (current incidence in children with shock in the unit) to 15% assuming a two-sided α level of 0.05 and a statistical power of 90%. The sample size was calculated using Stata 11. The investigators expect the required sample size to be collected within 3 years period in the three centers.
- Conditions
- Septic Shock, Shock
- Being tested
- Balanced crystalloid solution, 0.9%sodium chloride
- Keywords
- Normal saline, Multiple electrolyte solution, Septic shock, Children, Hyperchloremia, Acute kidney injury, 0.9% saline, Balanced crystalloid
- Medical subject headings
- Shock, Septic, Shock, Acute Kidney Injury
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Balanced crystalloid solutionDrug
Also called Plasma-Lyte A 148, Multiple electrolyte solution
Multiple electrolyte solution as boluses would be administered.
0.9%sodium chlorideDrug
Also called Saline
saline as boluses would be administered
| Study group | Role | What they receive |
|---|---|---|
| Balanced crystalloid or multiple electrolyte solution group | Experimental | After enrollment, a fluid bolus comprising of 'multiple electrolyte solution (Plasma-Lyte P)' solution at a dose of 20 ml/kg over 15-20 minutes (recommended) with careful monitoring for features of fluid overload would be administered to each child. Fluid resuscitation will be targeted at achieving the therapeutic end points as given in study definitions. After this the management protocol will be as per recommendations of the American College of Critical Care Medicine 2017 for septic shock in children. Receives: Drug: Balanced crystalloid solution |
| 0.9% saline or saline group | Active comparator | After enrollment, a fluid bolus comprising of 'saline' solution at a dose of 20 ml/kg over 15-20 minutes (recommended) with careful monitoring for features of fluid overload would be administered to each child. Fluid resuscitation will be targeted at achieving the therapeutic end points as given in study definitions. After this the management protocol will be as per recommendations of the American College of Critical Care Medicine 2017 for septic shock in children. Receives: Drug: 0.9%sodium chloride |
What is being measured
The primary outcome is the main question the study is designed to answer.
New or progressive acute kidney injury defined as increase in serum creatinine by > 0.3mg/dL within 48 hours or to 1.5 times baseline or more within the last 7 days or urine output less than 0.5 mL/kg/h for 6 hours
Incidence of new or progressive AKI in first 7 days after randomization/ intervention
Measured: From the time of randomization/intervention to 7 days of admission
Secondary outcomes (8)
Proportion of patients with serum chloride levels > 108 meq/L at admission, 6, 24, 48 and 72 hours
Incidence of hyperchloremia
Measured: At 6, 24, 48 and 72 hours after randomization
Number of fluid boluses received in the first 6 hours after randomization
Total number of fluid boluses received in the first 6 hours after randomization/intervention
Measured: From the time of randomization to 6 hours
Total fluids received in the first 24 hours, 24-48 hours and 48-72hrs in ml/kg after randomization
Total fluids received in first 24 hours, 24-48 hours and 48-72 hours
Measured: From the time of randomization to 72 hours
Mortality (serious adverse event)
Death during ICU course
Measured: From the time of randomization till death or discharge from ICU, whichever came first assessed upto 100 days
Time to resolution of AKI
Time taken for resolution of AKI
Measured: From the time of onset of AKI after randomization till death or discharge from hospital, whichever came first assessed upto 100 days
SOFA scores at 24 and 48 hours after randomization
Comparison of SOFA scores in both groups at 24 hours and 48 hours after randomization
Measured: At 24 and 48 hours after randomization
PELOD scores at 24 and 48 hours after randomization
Comparison of PELOD scores in both groups at 24 hours and 48 hours after randomization
Measured: At 24 and 48 hours after randomization
Incidence of metabolic acidosis at 6, 24, 48 and 72 hours after randomization
Comparison of number of children in both groups with acidosis at 6, 24, 48 and 72 hours after randomization
Measured: At admission and at 6, 24, 48 and 72 hours after randomization
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted15 Jul 2016 (estimated)
- Study start1 Apr 2017
- Primary completion15 Jan 2020
- Study completion15 Jan 2020
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Septic ShockStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- The enrolled children will be randomized to either balanced crystalloid (Plasma-Lyte A or multiple electrolyte solutions or MES group) or 0.9% saline (saline group).
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 708 participants (actual)
Sponsor and investigators
- Lead sponsor
- All India Institute of Medical Sciences
- Sponsor type
- University, hospital or other
- Collaborators
- Post Graduate Institute of Medical Education and Research, Chandigarh, Jawaharlal Institute of Postgraduate Medical Education & Research, St Johns Medical College Hospital, Bangalore, India
- Responsible party
- Principal investigator, Jhuma Sankar, All India Institute of Medical Sciences
- Investigators
- Jhuma Sankar, MD Ped, Principal investigator, All India Institute of Medical SciencesSushil K Kabra, MD Ped, Study chair, All India Institute of Medical SciencesRakesh Lodha, MD Ped, Study director, All India Institute of Medical Sciences
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02835157
- Sponsor's protocol ID
- IEC/NP-424/09.10.2015
- Status last verified
- Dec 2021
- First submitted
- 1 Mar 2016
- Last updated
- 21 Dec 2021
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: Individual patient data will not be shared
Publications
Sankar J, Muralidharan J, Lalitha AV, Rameshkumar R, Pathak M, Das RR, Nadkarni VM, Ismail J, Subramanian M, Nallasamy K, Dev N, Kumar UV, Kumar K, Sharma T, Jaravta K, Thakur N, Aggarwal P, Jat KR, Kabra SK, Lodha R. Multiple Electrolytes Solution Versus Saline as Bolus Fluid for Resuscitation in Pediatric Septic Shock: A Multicenter Randomized Clinical Trial. Crit Care Med. 2023 Nov 1;51(11):1449-1460. doi: 10.1097/CCM.0000000000005952. Epub 2023 Jun 9.
PubMed 37294145
Study at a glance
From the registry record, last updated by the sponsor on 21 Dec 2021. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Multiple Electrolyte Solution vs. Saline in Pediatric Septic Shock
- ClinicalTrials.gov ID
- NCT02835157
- Acronym / sponsor ID
- IEC/NP-424/09.10.2015
- Conditions
- Septic Shock, Shock
- Keywords
- Normal saline, Multiple electrolyte solution, Septic shock, Children, Hyperchloremia, Acute kidney injury, 0.9% saline, Balanced crystalloid
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 708 participants (actual)
- Lead sponsor
- All India Institute of Medical SciencesUniversity, hospital or other
- Collaborators
- Post Graduate Institute of Medical Education and Research, Chandigarh, Jawaharlal Institute of Postgraduate Medical Education & Research, St Johns Medical College Hospital, Bangalore, India
- Study start
- 1 Apr 2017 (actual)
- Primary completion
- 15 Jan 2020 (actual)
- Study completion
- 15 Jan 2020 (actual)
- First posted
- 15 Jul 2016 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Fluid resuscitation is the cornerstone of pediatric shock management; current practices of fluid resuscitation in children are not evidence based. Normal saline is the preferred crystalloid recommended during initial resuscitation in shock, as the incidence of hyponatremia is lower with normal saline compared to all other fluids available and commonly used. However, normal saline has its own set of undesired physicochemical actions. Emerging data strongly indicate the increased incidence of hyperchloremia, metabolic acidosis and consequently, acute kidney injury associated with infusion of large volumes of normal saline. Balanced salt solutions or crystalloids, which have composition resembling plasma but lower chloride concentrations than normal saline, clearly decrease the risk of hyperchloremia and metabolic acidosis in adult as well as pediatric studies when used during the peri-operative period. The results favored balanced solutions in comparison to normal saline. Recent systematic reviews comparing balanced or buffered versus non-buffered fluids for surgery in adults favored the former solution as the metabolic derangements were less with the use of this type of fluid. In adult patients, the two solutions have been compared in various other settings as well such as in traumatic brain injury and in shock. The results favored balanced solutions in comparison to normal saline. However, in the non-surgical setting there is a paucity of evidence on the use of these solutions in children with shock and more evidence needs to be generated to support or refute the use of this fluid as compared to normal saline.
Given this background, the investigators decided to compare the effect of two solutions on the incidence of acute kidney injury in children resuscitated with either of the two fluids. Children receiving at least one fluid bolus at 20 ml/kg in the first hour would be enrolled and followed up for the proposed outcome variables. The investigators plan to enroll 708 patients over a period of 3 years. The investigators believe that the proposed study will provide answer to the research question of which of the fluids could be preferred for resuscitation.
Detailed description
Background
Fluid resuscitation is the cornerstone of pediatric shock management; current practices of fluid resuscitation in children are not evidence based. Emerging data strongly indicate the increased incidence of hyperchloremic metabolic acidosis and consequently, acute kidney injury associated with infusion of large volumes of normal saline in critically ill adults in shock. Balanced salt solutions or crystalloids, which have composition resembling plasma but lower chloride concentrations than normal saline, have shown to decrease the risk of hyperchloremia and metabolic acidosis in adult as well as pediatric studies when used during the peri-operative period. In adult patients, the two solutions have been compared in various other settings as well such as in traumatic brain injury and in shock. The results favored balanced solutions in comparison to normal saline. However, in the non-surgical setting there is a paucity of evidence on the use of these solutions in children with shock and more evidence needs to be generated to support or refute the use of this fluid as compared to normal saline.
Objectives
Primary To examine if use of 'balanced crystalloids (multiple electrolyte solution)" results in lower incidence of new or progressive Acute kidney injury (defined as increase in serum creatinine by > 0.3mg/dL within 48 hours or to 1.5 times baseline or more within the last 7 days or urine output less than 0.5 mL/kg/h for 6 hours) in the first seven days after initial fluid resuscitation as compared to saline.
Secondary
To evaluate the difference if any, between two fluid types with regard to the following secondary objectives such as:
- Incidence of hyperchloremia (defined as serum chloride levels >108 mEq/L) at 6, 24, 48 and 72 hrs of fluid resuscitation.
- Incidence of metabolic acidosis at 6, 24, 48 and 72 hrs of fluid resuscitation.
- Requirement of fluid boluses in first 6 hrs and total fluids in first 24 hours, 48 hours and 72 hours.
- Proportion of patients achieving the pre-determined therapeutic end points at 6, 24, 48 hours and 72 hours after fluid resuscitation.
- Need for inotrope therapy in first 7 days.
- Change in SOFA scores and PELOD scores at 24 hours and 48 hours.
- Time to resolution of AKI.
- In- ICU mortality rates.
- Ventilator free days, ICU free days and Hospital free days.
Site of study
Pediatric emergency and PICU, Department of Pediatrics, All India Institute of medical Sciences,New Delhi
Other sites
PGIMER, Chandigarh, JIPMER Puducherry and St Johns Medical College Bengaluru
Study Design
Randomized controlled trial (safety and superiority for kidney injury). Multicenter trial.
Study Duration
3 years
Study definitions
Septic shock is defined as children who have a suspected infection manifested by hypothermia or hyperthermia and have at least two clinical signs of decreased perfusion with or without hypotension such as decreased mental status, prolonged capillary refill of >2 secs (cold shock) or flash capillary refill (warm shock), diminished (cold shock) or bounding (warm shock) peripheral pulses, mottled cool extremities (cold shock), or decreased urine output of <1 ml/kg/hr).
Therapeutic end points
- Normal heart rate
- Appropriate-for-age mean arterial pressure (MAP) measured non-invasively;
- Normal pulses with no difference between peripheral and central pulses, warm extremities;
- Capillary refill time <2 seconds;
- Normal mental status;
- Urine output ≥ 1mL/kg/hr,
Hyperchloremia: Defined as serum chloride value of >108 meq/L, based on our laboratory cut off of 98-108 meq/L Metabolic acidosis: pH of less than 7.35 with serum bicarbonate < 24 meq/L with low to normal pCO2 (<40 mm Hg)
Acute kidney injury: An abrupt (within 48-hr) reduction in kidney function defined as an absolute increase in serum creatinine of more than or equal to 0.3 mg/dl, an increase in serum creatinine of more than or equal to 1.5 fold from the value preceding the abnormal value, or reduction in urine output (oliguria of less than 0.5 ml/kg per hour for >6-hr).
Enrollment
All children with features of shock as per standard definitions will be screened for eligibility. Of these, children who require at least one fluid bolus of 20 ml/kg will be enrolled. The eligible participants would be enrolled after obtaining informed consent from one of the parents.
Randomization
Once enrolled, the participants would be randomized into 2 groups. 'MES' or 'study group' will receive the balanced fluids and 'saline' or 'control group' will receive 0.9% saline. Process of randomization will be done by an investigator who will have no further role in collecting the baseline variables, applying intervention or analysis of outcome(s). Block randomization will be done in varying block sizes of 2 to 8. The random number table generated from computer software would be used for this purpose.
Sample size estimation
The investigators calculated that a sample size of 354 patients in each group (708 total) would be required to detect an absolute reduction in incidence of AKI from 25% (current incidence in children with shock in the unit) to 15% assuming a two-sided α level of 0.05 and a statistical power of 90%. The sample size was calculated using Stata 11. The investigators expect the required sample size to be collected within 3 years period in the three centers.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 2
- Model description
- The enrolled children will be randomized to either balanced crystalloid (Plasma-Lyte A or multiple electrolyte solutions or MES group) or 0.9% saline (saline group).
| Arm | Type | Receives |
|---|---|---|
| Balanced crystalloid or multiple electrolyte solution group | Experimental | Drug: Balanced crystalloid solutionAfter enrollment, a fluid bolus comprising of 'multiple electrolyte solution (Plasma-Lyte P)' solution at a dose of 20 ml/kg over 15-20 minutes (recommended) with careful monitoring for features of fluid overload would be administered to each child. Fluid resuscitation will be targeted at achieving the therapeutic end points as given in study definitions. After this the management protocol will be as per recommendations of the American College of Critical Care Medicine 2017 for septic shock in children. |
| 0.9% saline or saline group | Active comparator | Drug: 0.9%sodium chlorideAfter enrollment, a fluid bolus comprising of 'saline' solution at a dose of 20 ml/kg over 15-20 minutes (recommended) with careful monitoring for features of fluid overload would be administered to each child. Fluid resuscitation will be targeted at achieving the therapeutic end points as given in study definitions. After this the management protocol will be as per recommendations of the American College of Critical Care Medicine 2017 for septic shock in children. |
Who may qualify
- Ages
- 2 months to 15 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child
Key inclusion criteria (1 listed)
- Children 2 month to ≤ 15 years with features of septic shock - defined as children who have a suspected infection manifested by hypothermia or hyperthermia and have at least two clinical signs of decreased perfusion with or without hypotension
Key exclusion criteria (5 listed)
- Children receiving fluid boluses before enrollment
- Children with cardiogenic shock
- Known patient with chronic kidney disease with baseline deranged renal function (eGFR < 90 ml/1.73 m2/min)
- Severe malnutrition
- Children whose parents refuse to give an informed consent
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Balanced crystalloid solutionAlso: Plasma-Lyte A 148, Multiple electrolyte solutionMultiple electrolyte solution as boluses would be administered. | Drug | Balanced crystalloid or multiple electrolyte solution group |
| 0.9%sodium chlorideAlso: Salinesaline as boluses would be administered | Drug | 0.9% saline or saline group |
Primary outcome
New or progressive acute kidney injury defined as increase in serum creatinine by > 0.3mg/dL within 48 hours or to 1.5 times baseline or more within the last 7 days or urine output less than 0.5 mL/kg/h for 6 hours
Time frame: From the time of randomization/intervention to 7 days of admission
Incidence of new or progressive AKI in first 7 days after randomization/ intervention
8 secondary outcomes
Proportion of patients with serum chloride levels > 108 meq/L at admission, 6, 24, 48 and 72 hours
Time frame: At 6, 24, 48 and 72 hours after randomization
Number of fluid boluses received in the first 6 hours after randomization
Time frame: From the time of randomization to 6 hours
Total fluids received in the first 24 hours, 24-48 hours and 48-72hrs in ml/kg after randomization
Time frame: From the time of randomization to 72 hours
Mortality (serious adverse event)
Time frame: From the time of randomization till death or discharge from ICU, whichever came first assessed upto 100 days
Time to resolution of AKI
Time frame: From the time of onset of AKI after randomization till death or discharge from hospital, whichever came first assessed upto 100 days
SOFA scores at 24 and 48 hours after randomization
Time frame: At 24 and 48 hours after randomization
PELOD scores at 24 and 48 hours after randomization
Time frame: At 24 and 48 hours after randomization
Incidence of metabolic acidosis at 6, 24, 48 and 72 hours after randomization
Time frame: At admission and at 6, 24, 48 and 72 hours after randomization
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 21 Dec 2021.
- Derived from this study: PubMed 37294145Sankar J, Muralidharan J, Lalitha AV, Rameshkumar R, Pathak M, Das RR, Nadkarni VM, Ismail J, Subramanian M, Nallasamy K, Dev N, Kumar UV, Kumar K, Sharma T, Jaravta K, Thakur N, Aggarwal P, Jat KR, Kabra SK, Lodha R. Multiple Electrolytes Solution Versus Saline as Bolus Fluid for Resuscitation in Pediatric Septic Shock: A Multicenter Randomized Clinical Trial. Crit Care Med. 2023 Nov 1;51(11):1449-1460. doi: 10.1097/CCM.0000000000005952. Epub 2023 Jun 9.
- Individual participant dataSharing planned: No. Individual patient data will not be shared
Related trials for Septic Shock
Not yet recruiting
ICU-SUCCEED for Survivors of Acute Respiratory Failure and Their Caregivers
Acute Respiratory Failure, Critical Illness
Not yet recruitingObservational study
Longitudinal Trajectories of Myocardial Work in Patients With Sepsis
Sepsis, Septic Shock Hyperdynamic
RecruitingObservational study
Immunothrombosis With Septic Shock Undergoing Renal Replacement Therapy With the OXIRIS Membrane
Sepsis
Not yet recruitingObservational study
Serum GDF-15 and LGALS3BP as Prognostic Biomarkers in Sepsis
Sepsis, Septic Shock
RecruitingPhase 3
A Trial of Adjunctive Fludrocortisone (50mcg, 100mcg or Placebo) in Critically Ill Patients With Septic Shock Receiving Hydrocortisone, Evaluating Survival and Functional Recovery and the Influence of Transcriptomic Response
Septic Shock
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Jhuma Sankar, MD Ped principal investigator
All India Institute of Medical Sciences
Sushil K Kabra, MD Ped study chair
All India Institute of Medical Sciences
Rakesh Lodha, MD Ped study director
All India Institute of Medical Sciences
4 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Balanced crystalloid solution and 0.9%sodium chloride in people with Septic Shock and Shock, run by All India Institute of Medical Sciences at 4 sites in India.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 21 Dec 2021. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 4 sites in India. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
New or progressive acute kidney injury defined as increase in serum creatinine by > 0.3mg/dL within 48 hours or to 1.5 times baseline or more within the last 7 days or urine output less than 0.5 mL/kg/h for 6 hours (time frame: From the time of randomization/intervention to 7 days of admission). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT02835157, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 Dec 2021.